Brainstorm Cell Therapeutics (BCLI) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCLI shares.
View BCLI analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12 month price objectives for Brainstorm Cell Therapeutics' stock. Their BCLI share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts.

Brainstorm Cell Therapeutics' stock was trading at $1.64 at the start of the year. Since then, BCLI shares have increased by 79.3% and is now trading at $2.94.
View the best growth stocks for 2023 here.

Brainstorm Cell Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,870,000 shares, a drop of 9.2% from the April 30th total of 3,160,000 shares. Based on an average trading volume of 359,000 shares, the short-interest ratio is currently 8.0 days. Approximately 9.5% of the company's shares are sold short.
View Brainstorm Cell Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BCLI earnings forecast.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, March, 30th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (3.98%), Susquehanna International Group LLP (0.00%), Raymond James & Associates (0.45%), Liberty Wealth Management LLC (0.41%), Group One Trading L.P. (0.00%) and TRU Independence Asset Management 2 LLC (0.12%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc and Sankesh Abbhi.
View institutional ownership trends.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCLI stock can currently be purchased for approximately $2.94.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $115.87 million. The biotechnology company earns $-24,280,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.